AI-Powered Healthcare: Personalization, Clinical Trials & Genetic Medicine Breakthroughs

Artificial intelligence is reshaping healthcare by enabling personalized treatment regimens based on genetic and medical history, though its integration requires adjustments to healthcare infrastructure.

Upon patients’ arrival, their personal data and clinical information—including images, electrophysiology findings, genetic data, blood pressure, and medical notes—are gathered into AI systems with their consent.

This approach allows healthcare companies to be more proactive in providing information to both patients and providers, creating seamless experiences similar to those offered by consumer platforms like Amazon.

AI algorithms, such as machine learning and deep learning, improve diagnostic accuracy by identifying patterns in patient data, including image recognition for cancer, heart diseases, and neurological disorders.

In treatment, AI evaluates patient responses to therapies and selects optimal regimens based on genetic and clinical profiles, particularly improving outcomes in oncology.

AI also accelerates drug discovery by predicting drug efficacy and safety, identifying therapeutic targets, and designing more efficient clinical trials.

Forbes – Innovation

This week, more than 14,000 people convened in Las Vegas for the annual Adobe Summit. Not surprisingly, a lot of the conversations at the conference were centered on AI – including one panel discussion focused on how the technology can be used to personalize healthcare delivery.

This is a priority for healthcare because “unlike other industries, in healthcare your journey is like no other’s because your biology is like no other’s,” said Blue Shield of California CMO Jigar Shah.

But the industry has been slower to adopt technology, suggested Tory Smithe, who leads digital strategy for healthcare at Adobe, because of regulation, siloed systems and legacy technologies, which have made companies more conservative about digital transformation.

Shah said that one way healthcare systems can overcome that inertia is to see regulation as being aligned to serve patients. “The intent behind regulation is to protect the consumer,” he said. “So if you accept that, then you see it as a springboard,” he added, citing Blue Shield’s implementation of price transparency before it became a regulatory mandate.

Another benefit of AI and new technologies, said Lesley Spellmeyer, who manages personalization for Lilly, is that they allow healthcare companies to be more proactive in providing information to both patients and providers. “Doctors are people, and they go to Amazon,” she said, which means that healthcare companies should provide the same kind of seamless experiences.

In this week’s edition of InnovationRx, we look at the opportunities and challenges of using AI to personalize healthcare and speed up clinical trials, the future of genetic medicine, another big Lilly acquisition, and more.